Search research articles
Contact Us
Filters
Showing results (151-160 of 260) with videos related to
Page
of 26
Sort By:
Circulation
|
September 27, 2015
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Samia Mora, Michael P Caulfield, Jay Wohlgemuth, et al.
Nature Communications
|
April 8, 2025
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Deirdre K Tobias, Aruna D Pradhan, Edward K Duran, et al.
Clinical Chemistry
|
October 18, 2022
The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching
Maxence Noel, Daniel I Chasman, Samia Mora, et al.
JAMA Cardiology
|
November 23, 2022
Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo
Mark A Hlatky, Pedro Engel Gonzalez, JoAnn E Manson, et al.
Circulation. Genomic and Precision Medicine
|
July 15, 2021
Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women
Rikuta Hamaya, Samia Mora, Patrick R Lawler, et al.
The American Journal of Cardiology
|
March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)
Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Clinical Cardiology
|
November 20, 2018
Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis
Eve-Marie A Benson, Martin Tibuakuu, Di Zhao, et al.
Circulation
|
March 31, 2012
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study
Samia Mora, Nanette K Wenger, David A Demicco, et al.
Research Square
|
October 3, 2025
Immune and inflammatory resolution pathways through multi-omics using the AI-based Network Integration
Azam Yazdani, Anika Mijakovac, Franco Giulianini, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 30, 2024
Defining a Minimal Benchmark for Cardiovascular Risk Prediction Calculators in New England Electronic Health Record-Derived Cohort
Aniket N Zinzuwadia, Olga Mineeva, Chunying Li, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 260) with videos related to
Sort By:
Page
of 26
Circulation
|
September 27, 2015
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Samia Mora, Michael P Caulfield, Jay Wohlgemuth, et al.
Nature Communications
|
April 8, 2025
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Deirdre K Tobias, Aruna D Pradhan, Edward K Duran, et al.
Clinical Chemistry
|
October 18, 2022
The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching
Maxence Noel, Daniel I Chasman, Samia Mora, et al.
JAMA Cardiology
|
November 23, 2022
Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo
Mark A Hlatky, Pedro Engel Gonzalez, JoAnn E Manson, et al.
Circulation. Genomic and Precision Medicine
|
July 15, 2021
Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women
Rikuta Hamaya, Samia Mora, Patrick R Lawler, et al.
The American Journal of Cardiology
|
March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)
Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Clinical Cardiology
|
November 20, 2018
Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis
Eve-Marie A Benson, Martin Tibuakuu, Di Zhao, et al.
Circulation
|
March 31, 2012
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study
Samia Mora, Nanette K Wenger, David A Demicco, et al.
Research Square
|
October 3, 2025
Immune and inflammatory resolution pathways through multi-omics using the AI-based Network Integration
Azam Yazdani, Anika Mijakovac, Franco Giulianini, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 30, 2024
Defining a Minimal Benchmark for Cardiovascular Risk Prediction Calculators in New England Electronic Health Record-Derived Cohort
Aniket N Zinzuwadia, Olga Mineeva, Chunying Li, et al.
Page
of 26